The benefits include once-daily dosing, as opposed to two to four times daily as required with sulfasalazine
Your telehealth platform will inform you if this applies to your state
- Upon thawing, the protein refolds incorrectly or aggregates into non-functional clumps
What the potential upside is, and just as importantly, what we dont know
We believe our miniature, ultra long-acting implants, designed to improve medication adherence, have the potential to improve efficacy and minimize tolerability issues.
Other noteworthy phase 3 trial readouts in 2025 include: Novo Nordisks evoke/evoke+ , investigating oral semaglutide in patients with early Alzheimers disease, potentially expanding the utility of GLP-1s beyond cardiometabolic indications